A first-of-its kind clinical trial will test the effectiveness of cannabidiol (CBD) as a potential treatment option.
Investigators will test the hypothesis that oral CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD.
The study is the first to test whether CBD is effective in treating alcohol addiction and in treating PTSD in humans, and the first to examine the interaction between these treatment effects.
A better understanding of the basis of alcohol addiction may also be achieved.
Approximately 50 otherwise healthy adults with moderate or severe alcohol addiction and PTSD will be randomized and treated with either CBD (400 mg daily) or placebo, for a period of six weeks.
Results are expected in late 2019 and will provide guidance for a larger clinical trial.
In collaboration with the National Institutes of Health, the study will be led by the chair of New York University’s School of Medicine, department of Psychiatry, Charles Marmar, MD. Dr.Marmar is also director of the PTSD Research Program at Cohen Veterans Center for the Study of Post-Traumatic Stress and Traumatic Brain Injury.
Dr. Marmar’s research has led to breakthroughs in our understanding of PTSD through the study of police officers, soldiers in combat, veterans, and civilians who have been exposed to sudden, usually life-threatening events.